GeneDx Holdings Corp.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. It primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. The company also develops an AI-based platform for NGS analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. The compan… Read more
GeneDx Holdings Corp. (WGS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.054x
Based on the latest financial reports, GeneDx Holdings Corp. (WGS) has a cash flow conversion efficiency ratio of 0.054x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($15.77 Million) by net assets ($292.26 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
GeneDx Holdings Corp. - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how GeneDx Holdings Corp.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
GeneDx Holdings Corp. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GeneDx Holdings Corp. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dgb Financial
KO:139130
|
0.001x |
|
Shaanxi Sirui Advanced Materials Co. Ltd. A
SHG:688102
|
N/A |
|
HAZAMA ANDO CORP.
F:2PW
|
N/A |
|
Tibet Mineral Development Co Ltd
SHE:000762
|
0.009x |
|
Matterport Inc
NASDAQ:MTTR
|
-0.007x |
|
Shanghai Wanye Enterprises Co Ltd
SHG:600641
|
-0.076x |
|
Yinyi Real Estate Co Ltd
SHE:000981
|
0.011x |
|
Yantai Moon Co Ltd
SHE:000811
|
0.046x |
Annual Cash Flow Conversion Efficiency for GeneDx Holdings Corp. (2020–2024)
The table below shows the annual cash flow conversion efficiency of GeneDx Holdings Corp. from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $245.25 Million | $-28.50 Million | -0.116x | +85.29% |
| 2023-12-31 | $228.02 Million | $-180.15 Million | -0.790x | +37.20% |
| 2022-12-31 | $253.71 Million | $-319.15 Million | -1.258x | -156.37% |
| 2021-12-31 | $388.10 Million | $-190.43 Million | -0.491x | +97.69% |
| 2020-12-31 | $4.39 Million | $-93.13 Million | -21.223x | -- |